Cystic fibrosis investigators within the P30 Center require access to expertise and specialized equipment for their studies of CFTR expression and function. For both established CF laboratories and those new to CF research, a need has been identified for developing new cell lines expressing mutant and wild type CFTR, and for dedicated equipment and biophysical protocols necessary to assess CFTR function. In particular, we propose two specific aims:
Specific Aim 1. Cellular models expressing wild type and mutant CFTR will be developed and provided by Core A. These will include primary cells from murine and human lungs, novel lentiviral transduced cell lines, and innovative CF models derived by zinc finger endonuclease modification of the CFTR locus in vitro.
Specific Aim 2. Assistance, equipment and expertise necessary to perform functional assays of CFTR in the above cell models (Aim 1) will include fluorescent (halide sensitive) dye protocols, Ussing chamber assays and biophysical techniques (patch clamp) necessary to investigate CFTR activity and regulation. The Core will aid in the development/validation of new CF cell models;provide primary murine airway epithelial cells encoding specific CFTR mutations;and assist investigators with their experiments to test the effects of AF508 on CFTR protein stability and channel function. Collaborative studies involving metabolomic consequences of mutations in CFTR, discovery of peptides from the first cytosolic loop of CFTR that specifically block NBD1 TMD1 binding and numerous other NIH funded projects will also be assisted by the Core. Core A will foster interdisciplinary research by providing valuable new cell models and assays of CFTR expression and function to investigators less familiar with the requisite techniques, and contribute to innovative studies of CF pathogenesis and experimental therapy.
| Shei, Ren-Jay; Peabody, Jacelyn E; Kaza, Niroop et al. (2018) The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis. Curr Opin Pharmacol 43:152-165 |
| Gebert, Magdalena; Bartoszewska, Sylwia; Janaszak-Jasiecka, Anna et al. (2018) PIWI proteins contribute to apoptosis during the UPR in human airway epithelial cells. Sci Rep 8:16431 |
| Montoro, Daniel T; Haber, Adam L; Biton, Moshe et al. (2018) A revised airway epithelial hierarchy includes CFTR-expressing ionocytes. Nature 560:319-324 |
| Lutful Kabir, Farruk; Ambalavanan, Namasivayam; Liu, Gang et al. (2018) MicroRNA-145 Antagonism Reverses TGF-? Inhibition of F508del CFTR Correction in Airway Epithelia. Am J Respir Crit Care Med 197:632-643 |
| Shei, Ren-Jay; Peabody, Jacelyn E; Rowe, Steven M (2018) Functional Anatomic Imaging of the Airway Surface. Ann Am Thorac Soc 15:S177-S183 |
| Clancy, John Paul; Cotton, Calvin U; Donaldson, Scott H et al. (2018) CFTR modulator theratyping: Current status, gaps and future directions. J Cyst Fibros : |
| Plyler, Z E; Birket, S E; Schultz, B D et al. (2018) Non-obstructive vas deferens and epididymis loss in cystic fibrosis rats. Mech Dev : |
| Poore, T Spencer; Virella-Lowell, Isabel; Guimbellot, Jennifer S (2018) Potential pathogenicity of Inquilinus limosus in a pediatric patient with cystic fibrosis. Pediatr Pulmonol 53:E21-E23 |
| Heltshe, Sonya L; Rowe, Steven M; Skalland, Michelle et al. (2018) Ivacaftor-treated Patients with Cystic Fibrosis Derive Long-Term Benefit Despite No Short-Term Clinical Improvement. Am J Respir Crit Care Med 197:1483-1486 |
| Guimbellot, Jennifer; Solomon, George M; Baines, Arthur et al. (2018) Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations. J Cyst Fibros : |
Showing the most recent 10 out of 175 publications
